Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
Tóm tắt
Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an antidote in case of serious bleeding or when an emergency intervention needs immediate correction of coagulation. This study evaluated the potential of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of these drugs.
In a randomized, double-blind, placebo-controlled study, 12 healthy male volunteers received rivaroxaban 20 mg twice daily (n=6) or dabigatran 150 mg twice daily (n=6) for 2½ days, followed by either a single bolus of 50 IU/kg PCC (Cofact) or a similar volume of saline. After a washout period, this procedure was repeated with the other anticoagulant treatment. Rivaroxaban induced a significant prolongation of the prothrombin time (15.8±1.3 versus 12.3±0.7 seconds at baseline;
Prothrombin complex concentrate immediately and completely reverses the anticoagulant effect of rivaroxaban in healthy subjects but has no influence on the anticoagulant action of dabigatran at the PCC dose used in this study.
URL:
Từ khóa
Tài liệu tham khảo
European Medicines Agency (EMEA). CHMP assessment report for Xarelto (rivaroxaban). 2008. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WC500057122.pdf. Accessed March 28 2011.
Health Canada. Note of decision for Xarelto. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2009_xarelto_119111-eng.php. 2008. Accessed March 28 2011.
European Medicines Agency (EMEA). CHMP assessment report for Pradaxa (dabigatran). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000829/WC500041062.pdf. 2008. Accessed March 28 2011.
Health Canada. Note of decision for Pradax. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2008_pradax_114887-eng.php. 2008. Accessed March 28 2011.
US Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. 2010. Accessed March 28 2011.
Pezborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats (presented at the 21st International Congress on Thrombosis) [abstract]. Pathophysiol Haemost Thromb. 2010; 37: A10-OC251.
van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate (presented at the 13th Congress of the European Hematology Association) [abstract]. Haematologica. 2008; 93: 148–0370.
Sanquin. Cofact: summary of product characteristics. http://www.sanquin.nl/Sanquin-eng/sqn_Cofact_eng.nsf/All/F9B2/$FILE/M%201.3.1%20SPC%20ENG%202006-11-17.pdf. 2005. Accessed March 28 2011.
Van Ryn J, Dörr B, Kaspereit F, Krege W, Zeitler S, Pragst I. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits (presented at the 21st International Congress on Thrombosis) [abstract]. Pathophysiol Haemost Thromb. 2010; 37: A94–P486.